Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of imatinib mesylate: implication for vaccination regimens

Leukemia. 2006 Jan;20(1):154-7. doi: 10.1038/sj.leu.2404043.
No abstract available

Publication types

  • Comparative Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / metabolism
  • Benzamides
  • Cell Survival / drug effects
  • Cells, Cultured
  • Dendritic Cells / drug effects*
  • Dendritic Cells / immunology*
  • Dose-Response Relationship, Drug
  • Fusion Proteins, bcr-abl / drug effects
  • Fusion Proteins, bcr-abl / immunology
  • Humans
  • Imatinib Mesylate
  • Immunization
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy
  • Piperazines / pharmacology*
  • Pyrimidines / pharmacology*
  • Vaccination

Substances

  • Antigens, CD
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl